The NOAC you choose for stroke risk reduction in NVAF matters Only XARELTO ® provides all of the following: Once daily,* 24-hour stroke risk reduction 1,2 *Taken with evening meal. Proven data in high-risk patients with a mean CHADS 2 score of 3.5 †1 : Comorbidities included: Elderly (≥75 years) CHF Diabetes Prior stroke, TIA, or non-CNS SE Hypertension Moderate renal impairment ‡ Extensive clinical trial and real-world evidence— time and time again 1,3-16 Class-leading coverage † ‡ The most affordable NOAC with the lowest average out-of-pocket cost 17 As demonstrated in ROCKET AF. CrCl 30 mL/min-49 mL/min; as calculated by the Cockcroft-Gault formula. INDICATION XARELTO ® is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fi brillation (AF). There are limited data on the relative effectiveness of XARELTO ® and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled. IMPORTANT SAFETY INFORMATION WARNING: (A) PREMATURE DISCONTINUATION OF XARELTO ® INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA that can increase the risk of developing epidural or spinal hematomas in these patients include: Use of indwelling epidural catheters Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-infl ammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants, see Drug Interactions A history of traumatic or repeated epidural or spinal punctures A history of spinal deformity or spinal surgery Optimal timing between the administration of XARELTO ® and neuraxial procedures is not known Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary. Consider the benefi ts and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis. Premature discontinuation of any oral anticoagulant, including XARELTO ® , increases the risk of thrombotic events. If anticoagulation with XARELTO ® is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant. Epidural or spinal hematomas have occurred in patients treated with XARELTO ® who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors A. Premature discontinuation of XARELTO ® increases the risk of thrombotic events B. Spinal/epidural hematoma CHADS 2 = CHF; hypertension; aged ≥75 years; diabetes mellitus; prior stroke or TIA; CHF = congestive heart failure; CrCl = creatinine clearance; NOAC = non-vitamin K antagonist oral anticoagulant; non-CNS SE = non-central nervous system systemic embolism; NVAF = nonvalvular atrial fi brillation; TIA = transient ischemic attack. Please see accompanying Brief Summary of full Prescribing Information, including Boxed WARNINGS, or visit www.XareltoHCP.com/PI.